Socio-economic burden of rare diseases: A systematic review of cost of illness evidenceAris Angelis, Panos Kanavos|Health Policy|2014Cited by 303
Impact of Managed Entry Agreements on availability of and timely access to medicines: an ex-post evaluation of agreements implemented for oncology therapies in four countriesOlina Efthymiadou, Panos Kanavos|BMC Health Services Research|2022Cited by 21